Two new studies in the New England Journal of Medicine show malaria vaccine candidate advancing in Africa - Bill & Melinda Gates Foundation
Data in infants and young children reinforce case for phase III trial of RTS,S/AS
NEW ORLEANS -- Results published online today in the New England Journal of Medicine revealed that the world’s most clinically advanced malaria vaccine candidate provides both infants and young children with significant protection against malaria. Two separate phase II trials reaffirmed earlier study results and support the ongoing efforts, pending regulatory approvals, to launch the phase III study of GlaxoSmithKline (GSK) Biologicals’ RTS,S/AS vaccine candidate across Africa.
To read the full press release, visit the Malaria Vaccine Initiative web site.